(2R)-2-丙基哌嗪 | 439082-60-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: (2R)-2-丙基哌嗪
• 中文别名: 咪唑烷,4-丁基-,(4S)-
• 英文名称: (R)-2-propylpiperazine
• 英文别名: (2R)-2-propylpiperazine
• CAS: 439082-60-7
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: FNJWLOHHZVGUIX-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2R)-2-丙基哌嗪 在 sodium carbonate 作用下， 以 乙醇 、 异戊醇 为溶剂， 反应 2.5h， 生成 (R)-2-(2-propyl-4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-6-(trifluoromethyl)-1H-benzo[d]imidazole
  参考文献：
  名称：

  Design of Potent, Orally Available Antagonists of the Transient Receptor Potential Vanilloid 1. Structure−Activity Relationships of 2-Piperazin-1-yl-1H-benzimidazoles

  摘要：

  The vanilloid receptor-1 ( VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2-ylpiperazin-1-yl)-1H-benzo-[ d] imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant ( CFA).

  DOI：

  10.1021/jm060065y
• 作为产物：
  描述：

  N-芴甲氧羰基-D-正缬氨酸 在 哌啶 、 lithium aluminium tetrahydride 、 N-羟基-7-氮杂苯并三氮唑 、 PS-carbodiimide 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 38.0h， 生成 (2R)-2-丙基哌嗪
  参考文献：
  名称：

  Design of Potent, Orally Available Antagonists of the Transient Receptor Potential Vanilloid 1. Structure−Activity Relationships of 2-Piperazin-1-yl-1H-benzimidazoles

  摘要：

  The vanilloid receptor-1 ( VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2-ylpiperazin-1-yl)-1H-benzo-[ d] imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant ( CFA).

  DOI：

  10.1021/jm060065y

文献信息

• [EN] THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE<br/>[FR] COMPOSITIONS THÉRAPEUTIQUEMENT ACTIVES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2012171337A1

  公开（公告）日：2012-12-20

  Provided are compounds with the following structure, formula (I) pharmaceutically acceptable salts thereof, use of those compounds for treating cancer and pharmaceutical compositions comprising those compounds.

  提供具有以下结构、式(I)的化合物，其药学上可接受的盐，以及利用这些化合物治疗癌症的用途和包含这些化合物的药物组合物。
• Pharmaceutical compounds
  申请人：——

  公开号：US20040122001A1

  公开（公告）日：2004-06-24

  This invention relates to compounds of formula (I) where R 1 to R 12 , —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals. 1

  这项发明涉及到式(I)的化合物，其中R1至R12，—W—V—，—X—Y—，m和n的值如权利要求1中定义的，它们的制备和用作药物。
• Derivative having ppar agonistic activity
  申请人：Itai Akiko

  公开号：US20090286974A1

  公开（公告）日：2009-11-19

  A compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein Ring Q is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, optionally substituted fused aryl or optionally substituted fused heteroaryl, Y 1 is a bond or —NR 6 — or the like, Ring A is optionally substituted nonaromatic heterocyclediyl, a group of the formula: -Y 2 Z 1 - is a group of the formula: R 7 are each independently hydrogen, optionally substituted lower alkyl or the like, R 8 and R 9 are each independently hydrogen or optionally substituted lower alkyl, n is an integer between 1 and 3, Z 1 is a bond, —O—, —S— or —NR 9 —, Ring B is optionally substituted aromatic carbocyclediyl or optionally substituted aromatic heterocyclediyl, Y 3 is a bond, optionally substituted lower alkylene optionally intervened by —O—, optionally substituted lower alkenylene or the like, and Z 2 is COOR 3 or the like.

  化合物的公式（I）：其药物可接受的盐或溶剂，其中环Q是可选择的取代的单环芳基，可选择的取代的单环杂芳基，可选择的融合芳基或可选择的融合杂芳基，Y1是键或-NR6-或类似物，环A是可选择的取代的非芳香杂环二基，公式组：-Y2Z1-是公式组：R7各自独立地是氢，可选择的取代的低烷基或类似物，R8和R9各自独立地是氢或可选择的取代的低烷基，n是1到3之间的整数，Z1是键，-O-，-S-或-NR9-，环B是可选择的取代的芳香碳杂环二基或可选择的取代的芳香杂环二基，Y3是键，可选择的取代的低烷基，可选择地介入-O-，可选择的取代的低烯基或类似物，并且Z2是COOR3或类似物。
• US8097610B2
  申请人：——

  公开号：US8097610B2

  公开（公告）日：2012-01-17
• [EN] ALPHA-UNSUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-A] PYRIMIDINE AMIDE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMIDE PYRIMIDINE ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-a] À SUBSTITUTION ALPHA
  申请人：PANACOS PHARMACEUTICALS INC

  公开号：WO2008134035A1

  公开（公告）日：2008-11-06

  [EN] Methods of preventing, treating or delaying the onset of HIV in a subject by administering to the subject novel pharmaceutically active arylmethyl pyrazolo[1,5-a ]pyrimidine amide derivatives, or pharmaceutical compositions containing the same are described. Additionally, compounds of novel pharmaceutically active arylmethyl piperazine pyrazolo[l,5-a]pyrimidine amide derivatives and their use for the manufacture of specific medicaments are described.
  [FR] Cette invention concerne des méthodes permettant de prévenir, de traiter ou de retarder le début du VIH chez un sujet par administration audit sujet de nouveaux dérivés d'amide pyrimide arylmethyl pyrazolo[1,5-a ] présentant une activité pharmaceutique, ou de compositions pharmaceutiques contenant de tels dérivés. En outre, cette invention concerne des composés de dérivés d'amide pyrimide arylmethyl pyrazolo[1,5-a ] présentant une activité pharmaceutique ainsi que l'utilisation de ceux-ci pour la fabrication de médicaments spécifiques.